Company Description
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
The company’s products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection.
It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.
The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo.
The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
| Country | United States |
| Founded | 1997 |
| IPO Date | Oct 29, 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 93 |
| CEO | Hermann Luebbert |
Contact Details
Address: 120 Presidential Way, Suite 330 Woburn, Massachusetts 01801 United States | |
| Phone | 781 245 1325 |
| Website | biofrontera-us.com |
Stock Details
| Ticker Symbol | BFRI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001858685 |
| CUSIP Number | 09077D100 |
| ISIN Number | US09077D2099 |
| Employer ID | 47-3765675 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Hermann Luebbert Ph.D. | Chief Executive Officer, President and Chairman |
| Eugene Frederick Leffler III | Chief Financial Officer |
| Erica F. Gates CPA, M.B.A. | Senior Director of Finance and Principal Accounting Officer |
| Jon Lyons M.B.A., Ph.D. | Vice President of Scientific and Medical Affairs |
| Daniel Hakansson J.D. | General Counsel and Head of Compliance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 3, 2025 | 8-K | Current Report |
| Jun 3, 2025 | DEFR14A | Filing |
| May 23, 2025 | 8-K | Current Report |
| May 15, 2025 | 8-K | Current Report |
| May 15, 2025 | 10-Q | Quarterly Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 14, 2025 | 8-K | Current Report |
| May 13, 2025 | SCHEDULE 13G/A | Filing |
| Apr 30, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 18, 2025 | 8-K | Current Report |